Adverse event diagnoses (n = 540) in 421 reports grouped according to organ system disorder and seriousness*
| Organ system disorder | Non-serious (n = 423) | Serious (n = 102) | Total (n = 540) |
|---|---|---|---|
| Values are n (%). | |||
| *Organ system disorder according to the Swedish Medical Products Agency diagnostic classification. Seriousness missing in 15 diagnoses (2.8%). | |||
| †Includes increased infection susceptibility and opportunistic infections. | |||
| Skin | 122 (28.8%) | 8 (7.8%) | 134 (24.8%) |
| Infection resistance mechanism† | 66 (15.6%) | 20 (19.6%) | 90 (16.7%) |
| Respiratory system | 62 (14.7%) | 10 (9.8%) | 74 (13.7%) |
| General | 61 (14.4%) | 8 (7.8%) | 70 (13.0%) |
| Neurological | 19 (4.5%) | 9 (8.8%) | 29 (5.4%) |
| Gastrointestinal | 25 (5.9%) | 3 (2.9%) | 28 (5.2%) |
| Cardiovascular | 11 (2.6%) | 15 (14.7%) | 26 (4.8%) |
| Haematological | 8 (1.9%) | 9 (8.8%) | 17 (3.2%) |
| Musculoskeletal | 11 (2.6%) | 1 (1.0%) | 12 (2.2%) |
| Neoplasms | 0 | 11 (10.8%) | 11 (2.0%) |
| Vision/eye | 10 (2.4%) | 1 (1.0%) | 11 (2.0%) |
| Female reproductive | 6 (1.4%) | 1 (1.0%) | 8 (1.5%) |
| Urinary system | 4 (1.0%) | 2 (2.0%) | 7 (1.3%) |
| Metabolic | 3 (0.7%) | 2 (2.0%) | 5 (0.9%) |
| Psychiatric | 4 (1.0%) | 1 (1.0%) | 5 (0.9%) |
| Hearing/vestibular | 4 (1.0%) | 0 | 4 (0.7%) |
| Liver/biliary | 2 (0.5%) | 1 (1.0%) | 3 (0.6%) |
| Odontological | 2 (0.5%) | 0 | 3 (0.6%) |
| Drug related collagenosis | 2 (0.5%) | 0 | 2 (0.4%) |
| Endocrine | 1 (0.2%) | 0 | 1 (0.2%) |